Marchesi F, Pimpinelli F, Gumenyuk S, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Ensoli F, Mengarelli A. Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study. World J Transplant 2015; 5(3): 129-136 [PMID: 26421265 DOI: 10.5500/wjt.v5.i3.129]
Corresponding Author of This Article
Francesco Marchesi, MD, Hematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Via E. Chianesi 53, 00144 Rome, Italy. marchesi.francesco@tiscali.it
Research Domain of This Article
Hematology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Marchesi F, Pimpinelli F, Gumenyuk S, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Ensoli F, Mengarelli A. Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study. World J Transplant 2015; 5(3): 129-136 [PMID: 26421265 DOI: 10.5500/wjt.v5.i3.129]
World J Transplant. Sep 24, 2015; 5(3): 129-136 Published online Sep 24, 2015. doi: 10.5500/wjt.v5.i3.129
Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study
Francesco Marchesi, Fulvia Pimpinelli, Svitlana Gumenyuk, Daniela Renzi, Francesca Palombi, Francesco Pisani, Atelda Romano, Antonio Spadea, Elena Papa, Marco Canfora, Fabrizio Ensoli, Andrea Mengarelli
Francesco Marchesi, Svitlana Gumenyuk, Daniela Renzi, Francesca Palombi, Francesco Pisani, Atelda Romano, Antonio Spadea, Elena Papa, Andrea Mengarelli, Hematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, 00144 Rome, Italy
Fulvia Pimpinelli, Fabrizio Ensoli, Molecular Virology, Pathology and Microbiology Laboratory, San Gallicano Dermatological Institute, 00144 Rome, Italy
Marco Canfora, Scientific Direction, Regina Elena National Cancer Institute, 00144 Rome, Italy
Author contributions: Marchesi F and Mengarelli A contributed to the concept and design of the study; Marchesi F, Gumenyuk S, Renzi D, Palombi F, Pisani F, Romano A and Spadea A performed the clinical management and data collection; Pimpinelli F and Ensoli F performed the virological laboratory studies; Marchesi F, Papa E and Canfora M made the data analysis and interpretation; Marchesi F wrote the manuscript; Marchesi F and Mengarelli A made the final critical revision of the manuscript.
Institutional review board statement: The study was approved by the institutional Ethical Committee without a formal document, considering that all patients had signed an informed consent granting use of sensitive data for scientific purposes at time of admission in our Institute.
Informed consent statement: All the patients had signed an informed consent granting use of sensitive data for scientific purposes at time of admission in our Institute.
Conflict-of-interest statement: No disclosures.
Data sharing statement: No additional data are available.
Correspondence to: Francesco Marchesi, MD, Hematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Via E. Chianesi 53, 00144 Rome, Italy. marchesi.francesco@tiscali.it
Telephone: +39-6-52665022 Fax: +39-6-52662849
Received: May 8, 2015 Peer-review started: May 9, 2015 First decision: June 3, 2015 Revised: June 12, 2015 Accepted: July 7, 2015 Article in press: July 8, 2015 Published online: September 24, 2015 Processing time: 139 Days and 13.9 Hours
Core Tip
Core tip: Data about cytomegalovirus (CMV) reactivation in autologous hematopoietic stem cell transplantation (ASCT) are limited. We performed a retrospective observational study on 327 autografts consecutively performed for lymphoma (n = 126) or myeloma (n = 201) patients in our Institution. Aim of the study was to determine the incidence of and the risk factors for CMV symptomatic infection and/or end-organ disease, defined according to published recommendations, and the impact on Transplant-Related Mortality. Our data show that a symptomatic CMV infection can occur in about 11% of adult patients with lymphoma or myeloma undergoing ASCT. Most of cases of CMV reactivation are easily manageable but it can be a potentially life-threatening complication. As for risk factors, a pre-transplant HBcIgG seropositivity and a diagnosis of T-cell non-Hodgkin’s lymphoma should be considered as independent risk factors for CMV reactivation after ASCT.
